EpiCast Report: Epilepsy - Epidemiology Forecast to 2022

Feb. 2, 2013 - PRLog -- The number of epilepsy cases in the US will increase by 10.3% over the next decade according to the latest report by research and intelligence firm GlobalData.

The company’s new epidemiology report*forecasts that the active prevalent cases of epilepsy will increase from an estimated 2.2 million in 2012 to an estimated 2.5 million cases by 2022.

Although millions of people in the US are affected by epilepsy, the condition is still understudied. GlobalData’s specialized epidemiology analysts explain that a treatment gap exists in the US, primarily due to the adverse effects of medications used to treat epilepsy and the limited access to therapeutic options, particularly surgical intervention.

According to the GlobalData epidemiologists, of the nine major markets studied (the US, China, India, Japan, and the five top European markets), India will have the highest active prevalence of epilepsy with around 8 million cases in 2022, while China will have the second greatest with an estimated 5.1 million cases.

For Sample Pages, please click or add the below link to your browser:

http://store.globaldata.com/market-reports/pharmaceuticals-and-healthcare/EpiCast-Report-Epilepsy-Epidemiology-Forecast-to-2022/sample&CompanyID=prlog (http://store.globaldata.com/market-reports/pharmaceutical...)

High prevalence numbers in both of these countries are attributed primarily to their large populations, while both also have significant treatment gaps due to social stigma surrounding epilepsy.

This report provides an overview of risk factors and global trends for epilepsy in the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) along with emerging markets—India and China.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:

http://store.globaldata.com/market-reports/pharmaceuticals-and-healthcare/EpiCast-Report-Epilepsy-Epidemiology-Forecast-to-2022&CompanyID=prlog (http://store.globaldata.com/market-reports/pharmaceutical...)

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:pressreleases@globaldata.com


North America:          +1 646 395 5477

Europe:          +44 207 753 4299

         +44 1204 543 533

Asia Pacific:          +91 40 6616 6782